Intratumoural inflammation and endocrine resistance in breast cancer

Endocrine-Related Cancer

Volumn 22, Issue 1, 2015, Pages R51-R67

  Murray, Jill I ^a   West, Nathan R ^b   Murphy, Leigh C ^c   Watson, Peter H ^a,d,e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF VICTORIA   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomarker; Breast; Endocrine therapy resistance; Estrogen receptor; Molecular immunology

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR ALPHA; POLYPEPTIDE ANTIBIOTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER RESISTANCE; CYTOKINE PRODUCTION; ENDOCRINOLOGY; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; INFLAMMATORY BREAST NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; INFLAMMATION; INFLAMMATORY BREAST NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 84923591240     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0096     Document Type: Review

References (186)

1. Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y, Hiller-Hitchcock T, Hole K, Murphy LC & Watson PH 1999 Psoriasin (S100A7) expression and invasive breast cancer. American Journal of Pathology 155 2057-2066. (doi:10.1016/S0002-9440(10)65524-1)
2. Alowami S, Qing G, Emberley E, Snell L & Watson PH 2003 Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatology 3 1. (doi:10.1186/1471-5945-3-1)
3. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C & Loi S 2013 Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clinical Cancer Research 19 28-33. (doi:10.1158/1078-0432.CCR-11-2701)
4. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM et al. 2011 IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clinical Cancer Research 17 2538-2548. (doi:10.1158/1078-0432.CCR-10-3314)
5. Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA & Burow ME 2012 Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation. Cancer Biology & Therapy 13 1026-1033. (doi:10.4161/cbt.20992)
6. Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV et al. 2013 MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. PLoS ONE 8 e69291. (doi:10.1371/journal. pone.0069291)
7. Arnett E & Seveau S 2011 The multifaceted activities of mammalian defensins. Current Pharmaceutical Design 17 4254-4269. (doi:10.2174/138161211798999348)
8. Arpino G, Wiechmann L, Osborne CK & Schiff R 2008 Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine Reviews 29 217-233. (doi:10.1210/er.2006-0045)
9. Arteaga CL, Koli KM, Dugger TC & Clarke R 1999 Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-b. Journal of the National Cancer Institute 91 46-53. (doi:10.1093/jnci/91.1.46)
10. Balkwill FR & Mantovani A 2012 Cancer-related inflammation: common themes and therapeutic opportunities. Seminars in Cancer Biology 22 33-40. (doi:10.1016/j.semcancer.2011.12.005)
11. Balkwill F, Charles KA & Mantovani A 2005 Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 211-217. (doi:10.1016/j.ccr.2005.02.013)
12. Baumgarten SC & Frasor J 2012 Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Molecular Endocrinology 26 360-371. (doi:10.1210/me.2011-1302)
13. Bayliss J, Hilger A, Vishnu P, Diehl K & El-Ashry D 2007 Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clinical Cancer Research 13 7029-7036. (doi:10.1158/1078-0432.CCR-07-0587)
14. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M & West RB 2009 The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clinical Cancer Research 15 778-787. (doi:10.1158/1078-0432.CCR-08-1283)
15. Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH et al. 2010 FOXA1 is an essential determinant of ERa expression and mammary ductal morphogenesis. Development 137 2045-2054. (doi:10.1242/dev.043299)
16. Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ et al. 2013 FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene 32 554-563. (doi:10.1038/onc.2012.62)
17. Bertucci F, Finetti P & Birnbaum D 2012 Basal breast cancer: a complex and deadly molecular subtype. Current Molecular Medicine 12 96-110. (doi:10.2174/156652412798376134)
18. Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS, Ali S & Nakshatri H 2004 Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. British Journal of Cancer 90 853-859. (doi:10.1038/sj.bjc.6601541)
19. Billam M, Witt AE & Davidson NE 2009 The silent estrogen receptor - can we make it speak? Cancer Biology & Therapy 8 485-496. (doi:10.4161/cbt.8.6.7582)
20. Biswas SK, Allavena P & Mantovani A 2013 Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Seminars in Immunopathology 35 585-600. (doi:10.1007/s00281-013-0367-7)
21. Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A & Baumann H 2001 Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor a, and oncostatin M receptor b by distinct mechanisms. Journal of Biological Chemistry 276 47038-47045. (doi:10.1074/jbc.M107971200)
22. Bolin C, Tawara K, Sutherland C, Redshaw J, Aranda P, Moselhy J, Anderson R & Jorcyk CL 2012 Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation. Genes & Cancer 3 117-130. (doi:10.1177/1947601912458284)
23. Brinkman JA & El-Ashry D 2009 ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. Journal of Mammary Gland Biology and Neoplasia 14 67-78. (doi:10.1007/s10911-009-9113-0)
24. Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S & Goloubeva O 2005 Therapeutic observations in MCF-7 aromatase xenografts. Clinical Cancer Research 11 884s-888s.
25. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM & Clemons MJ 2009 Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Research 29 1557-1562.
26. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
27. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO et al. 2011 Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Research and Treatment 128 703-711. (doi:10.1007/s10549-010-1154-y)
28. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D & Esserman LJ 2013 The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS ONE 8 e79114. (doi:10.1371/journal.pone.0079114)
29. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S & Lazennec G 2007 Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Research 9 R15. (doi:10.1186/bcr1648)
30. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM & Nielsen TO 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research 14 1368-1376. (doi:10.1158/1078-0432.CCR-07-1658)
31. Chen SH & Benveniste EN 2004 Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine & Growth Factor Reviews 15 379-391. (doi:10.1016/j.cytogfr.2004.06.002)
32. C breast cancer. Clinical Cancer Research 20 3222-3232. (doi:10.1158/1078-0432.CCR-13-3227)
33. Coussens LM & Werb Z 2002 Inflammation and cancer. Nature 420 860-867. (doi:10.1038/nature01322)
34. Coussens LM, Zitvogel L & Palucka AK 2013 Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339 286-291. (doi:10.1126/science.1232227)
35. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM & El-Ashry D 2006 Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors. Cancer Research 66 3903-3911. (doi:10.1158/0008-5472.CAN-05-4363)
36. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG et al. 2010 Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ERC breast cancer. Breast Cancer Research 12 R40. (doi:10.1186/bcr2594)
37. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB & Lee AV 2003 Insulinlike growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Molecular Endocrinology 17 575-588. (doi:10.1210/me.2002-0318)
38. Cui X, Schiff R, Arpino G, Osborne CK & Lee AV 2005 Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. Journal of Clinical Oncology 23 7721-7735. (doi:10.1200/JCO.2005.09.004)
39. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al. 2012 The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486 346-352. (doi:10.1038/nature10983)
40. D'Anello L, Sansone P, Storci G, Mitrugno V, D'Uva G, Chieco P & Bonafe M 2010 Epigenetic control of the basal-like gene expression profile via interleukin-6inbreast cancercells.Molecular Cancer9300. (doi:10.1186/1476-4598-9-300)
41. DeNardo DG & Coussens LM 2007 Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research 9 212. (doi:10.1186/bcr1746)
42. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA et al. 2011 Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery 1 54-67. (doi:10.1158/2159-8274.CD-10-0028)
43. De Palma M & Lewis CE 2013 Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23 277-286. (doi:10.1016/j.ccr.2013.02.013)
44. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M & Sotiriou C 2008 Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clinical Cancer Research 14 5158-5165. (doi:10.1158/1078-0432.CCR-07-4756)
45. Dhasarathy A, Kajita M & Wade PA 2007 The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-a. Molecular Endocrinology 21 2907-2918. (doi:10.1210/me.2007-0293)
46. CT cells and enhanced expression of the chemokine psoriasin in normal human skin. Photochemistry and Photobiology 72 374-382. (doi:10.1562/0031-8655(2000)0720374ETUIAO2.0.CO2)
47. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C & Gerald WL 2006 An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25 3994-4008. (doi:10.1038/sj.onc.1209415)
48. Dunn GP, Old LJ & Schreiber RD 2004 The three Es of cancer immunoediting. Annual Review of Immunology 22 329-360. (doi:10.1146/annurev.immunol.22.012703.104803)
49. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 1687-1717. (doi:10.1016/S0140-6736(05)66544-0)
50. Ehrchen JM, Sunderkotter C, Foell D, Vogl T & Roth J 2009 The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. Journal of Leukocyte Biology 86 557-566. (doi:10.1189/jlb.1008647)
51. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC et al. 2012 Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486 353-360. (doi:10.1038/nature11143)
52. Emberley ED, Niu Y, Leygue E, Tomes L, Gietz RD, Murphy LC & Watson PH 2003 Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Research 63 1954-1961.
53. Emberley ED, Alowami S, Snell L, Murphy LC & Watson PH 2004 S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast. Breast Cancer Research 6 R308-R315. (doi:10.1186/bcr791)
54. Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, Myers JN, Gibson SB, Murphy LC & Watson PH 2005 The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Research 65 5696-5702. (doi:10.1158/0008-5472.CAN-04-3927)
55. Faridi J, Wang L, Endemann G & Roth RA 2003 Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clinical Cancer Research 9 2933-2939.
56. Foell D, Wittkowski H, Vogl T & Roth J 2007 S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. Journal of Leukocyte Biology 81 28-37. (doi:10.1189/jlb.0306170)
57. Fornetti J, Jindal S, Middleton KA, Borges VF & Schedin P 2014 Physiological COX-2 expression in breast epithelium associates with COX-2 levels in ductal carcinoma in situ and invasive breast cancer in young women. American Journal of Pathology 184 1219-1229. (doi:10.1016/j.ajpath.2013.12.026)
58. Frend HT & Watson CJ 2013 Elf5 - breast cancer's little helper. Breast Cancer Research 15 307. (doi:10.1186/bcr3397)
59. Garber K 2009 First results for agents targeting cancer-related inflammation. Journal of the National Cancer Institute 101 1110-1112. (doi:10.1093/jnci/djp266)
60. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R & Royuela M 2008 OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). Cancer Investigation 26 222-229. (doi:10.1080/07357900701638491)
61. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M et al. 2005 Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocrine-Related Cancer 12 (Suppl 1) S1-S7. (doi:10.1677/erc.1.01054)
62. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C et al. 2011 Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nature Medicine 17 715-719. (doi:10.1038/nm.2351)
63. Gilbert CA & Slingerland JM 2013 Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annual Review of Medicine 64 45-57. (doi:10.1146/annurev-med-121211-091527)
64. Glaser R, Harder J, Lange H, Bartels J, Christophers E & Schroder JM 2005 Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nature Immunology 6 57-64. (doi:10.1038/ni1142)
65. Goldberg JE & Schwertfeger KL 2010 Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Current Drug Targets 11 1133-1146. (doi:10.2174/138945010792006799)
66. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ & Panel M 2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of Oncology 20 1319-1329. (doi:10.1093/annonc/mdp322)
67. de Graffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW & Weiss GR 2004 NF-k B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Annals of Oncology 15 885-890. (doi:10.1093/annonc/mdh232)
68. Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK & Begley CG 2002 An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene 21 460-474. (doi:10.1038/sj.onc.1205100)
69. Guo S & Sonenshein GE 2004 Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Molecular and Cellular Biology 24 8681-8690. (doi:10.1128/MCB.24.19.8681-8690.2004)
70. Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qian L & GuoN 2013 Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene 32 5272-5282. (doi:10.1038/onc.2012.573)
71. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK & Dowsett M 2005 Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 23 2469-2476. (doi:10.1200/JCO.2005.01.172)
72. Guttilla IK, Adams BD & White BA 2012 ERa, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends in Endocrinology and Metabolism 23 73-82. (doi:10.1016/j.tem.2011.12.001)
73. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR & Binder C 2004 Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-α dependent up-regulation of matrix metalloproteases. Carcinogenesis 25 1543-1549. (doi:10.1093/carcin/bgh146)
74. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C & Balkwill FR 2005 Macrophages induce invasiveness of epithelial cancer cells via NF-k B and JNK. Journal of Immunology 175 1197-1205. (doi:10.4049/jimmunol.175.2.1197)
75. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al. 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology 28 2784-2795. (doi:10.1200/JCO.2009.25.6529)
76. Hanahan D & Coussens LM 2012 Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21 309-322. (doi:10.1016/j.ccr.2012.02.022)
77. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013)
78. Harder J, Glaser R & Schroder JM 2007 Human antimicrobial proteins effectors of innate immunity. Journal of Endotoxin Research 13 317-338. (doi:10.1177/0968051907088275)
79. Hartman J, Strom A & Gustafsson JA 2009 Estrogen receptor beta in breast cancer - diagnostic and therapeutic implications. Steroids 74 635-641. (doi:10.1016/j.steroids.2009.02.005)
80. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkila P, Perou CM et al. 2012 Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. PNAS 109 2742-2747. (doi:10.1073/pnas.1106509108)
81. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G & Schaper F 2003 Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal 374 1-20. (doi:10.1042/BJ20030407)
82. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S et al. 2007 Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology 8 R76. (doi:10.1186/gb-2007-8-5-r76)
83. Hintzen C, Quaiser S, Pap T, Heinrich PC & Hermanns HM 2009 Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthritis and Rheumatism 60 1932-1943. (doi:10.1002/art.24602)
84. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D & Hankinson SE 2010 Aspirin intake and survival after breast cancer. Journal of Clinical Oncology 28 1467-1472. (doi:10.1200/JCO.2009.22.7918)
85. Howe LR, Subbaramaiah K, Hudis CA & Dannenberg AJ 2013 Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clinical Cancer Research 19 6074-6083. (doi:10.1158/1078-0432.CCR-12-2603)
86. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S & Sotiriou C 2012 Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. Journal of Clinical Oncology 30 1996-2004. (doi:10.1200/JCO.2011.39.5624)
87. Jiang X & Shapiro DJ 2014 The immune system and inflammation in breast cancer. Molecular and Cellular Endocrinology 382 673-682. (doi:10.1016/j.mce.2013.06.003)
88. Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser B, Etzerodt M, Honore B, Celis JE & Thestrup-Pedersen K 1996 Psoriasin: a novel chemotactic protein. Journal of Investigative Dermatology 107 5-10. (doi:10.1111/1523-1747.ep12294284)
89. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR & Dowsett M 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Research 55 3331-3338.
90. Jones SA, Scheller J & Rose-John S 2011 Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation 121 3375-3383. (doi:10.1172/JCI57158)
91. Jonsson P, Katchy A & Williams C 2014 Support of a bi-faceted role of estrogen receptor b (ERb) in ERa-positive breast cancer cells. Endocrine-Related Cancer 21 143-160. (doi:10.1530/ERC-13-0444)
92. Jorcyk CL, Holzer RG & Ryan RE 2006 Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine 33 323-336. (doi:10.1016/j.cyto.2006.03.004)
93. Kaklamani V 2006 A genetic signature can predict prognosis and response to therapy in breast cancer: oncotype DX. Expert Review of Molecular Diagnostics 6 803-809. (doi:10.1586/14737159.6.6.803)
94. Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R et al. 2012 ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biology 10 e1001461. (doi:10.1371/journal.pbio.1001461)
95. Kastl SP, Speidl WS, Kaun C, Katsaros KM, Rega G, Afonyushkin T, Bochkov VN, Valent P, Assadian A, Hagmueller GW et al. 2008 In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. Arteriosclerosis, Thrombosis, and Vascular Biology 28 498-503. (doi:10.1161/ATVBAHA.107.160580)
96. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL & Rimm DL 2004 Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clinical Cancer Research 10 173-177. (doi:10.1158/1078-0432.CCR-0699-3)
97. Kronblad A, Hedenfalk I, Nilsson E, Pahlman S & Landberg G 2005 ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERa: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 24 6835-6841. (doi:10.1038/sj.onc.1208830)
98. Kuukasjarvi T, Kononen J, Helin H, Holli K & Isola J 1996 Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. Journal of Clinical Oncology 14 2584-2589.
99. Kwan ML, Habel LA, Slattery ML & Caan B 2007 NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes & Control 18 613-620. (doi:10.1007/s10552-007-9003-y)
100. Lapidus RG, Nass SJ & Davidson NE 1998 The loss of estrogen and progesterone receptor gene expression in human breast cancer. Journal of Mammary Gland Biology and Neoplasia 3 85-94. (doi:10.1023/A:1018778403001)
101. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y & Pietenpol JA 2011 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 121 2750-2767. (doi:10.1172/JCI45014)
102. Levano KS, Jung EH & Kenny PA 2011 Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines. Biochemical and Biophysical Research Communications 411 107-110. (doi:10.1016/j.bbrc.2011.06.102)
103. Lewis JS & Jordan VC 2005 Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutation Research 591 247-263. (doi:10.1016/j.mrfmmm.2005.02.028)
104. Lewis CE & Pollard JW 2006 Distinct role of macrophages in different tumor microenvironments. Cancer Research 66 605-612. (doi:10.1158/0008-5472.CAN-05-4005)
105. Leygue E, Snell L, Hiller T, Dotzlaw H, Hole K, Murphy LC & Watson PH 1996 Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma. Cancer Research 56 4606-4609.
106. Lim E, Metzger-Filho O & Winer EP 2012 The natural history of hormone receptor-positive breast cancer. Oncology 26 688-694.
107. Clymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Research 14 R48. (doi:10.1186/bcr3148)
108. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF et al. 2008 Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9 239. (doi:10.1186/1471-2164-9-239)
109. C lymphocytes predict clinical outcome in breast cancer. Journal of Clinical Oncology 29 1949-1955. (doi:10.1200/JCO.2010.30.5037)
110. Man J & Zhang X 2011 CUEDC2: an emerging key player ininflammationand tumorigenesis. Protein& Cell 2699-703.(doi:10.1007/s13238-011-1089-z)
111. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S & Schiff R 2006 Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Research 66 8266-8273. (doi:10.1158/0008-5472.CAN-05-4045)
112. Medrek C, Ponten F, Jirstrom K & Leandersson K 2012 The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12 306. (doi:10.1186/1471-2407-12-306)
113. Miller TW, Balko JM & Arteaga CL 2011 Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Journal of Clinical Oncology 29 4452-4461. (doi:10.1200/JCO.2010.34.4879)
114. Motomura K, Ishitobi M, Komoike Y, Koyama H, Nagase H, Inaji H & Noguchi S 2010 Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology 79 55-61. (doi:10.1159/000319540)
115. Murphy LC & Leygue E 2012 The role of estrogen receptor-β in breast cancer. Seminars in Reproductive Medicine 30 5-13. (doi:10.1055/s-0031-1299592)
116. Murphy LC & Watson PH 2006 Is oestrogen receptor-β a predictor of endocrine therapy responsiveness in human breast cancer? Endocrine-Related Cancer 13 327-334. (doi:10.1677/erc.1.01141)
117. Murphy LC & Watson P 2002 Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomedicine & Pharmacotherapy 56 65-77. (doi:10.1016/S0753-3322(01)00157-3)
118. Murphy LC, Leygue E, Niu Y, Snell L, Ho SM & Watson PH 2002 Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. British Journal of Cancer 87 1411-1416. (doi:10.1038/sj.bjc.6600654)
119. Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, Ung K, Vendetti M & Shiu R 2005 Inducible upregulation of oestrogen receptor-b1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. Journal of Molecular Endocrinology 34 553-566. (doi:10.1677/jme.1.01688)
120. Murphy LC, Seekallu SV & Watson PH 2011 Clinical significance of estrogen receptor phosphorylation. Endocrine-Related Cancer 18 R1-R14. (doi:10.1677/ERC-10-0070)
121. Musgrove EA & Sutherland RL 2009 Biological determinants of endocrine resistance in breast cancer. Nature Reviews. Cancer 9 631-643. (doi:10.1038/nrc2713)
122. Nagaraj G, Ellis MJ & Ma CX 2012 The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept. Oncology 26 696-697, 700.
123. Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X et al. 2012 S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Research 72 604-615. (doi:10.1158/0008-5472.CAN-11-0669)
124. Naugler WE & Karin M 2008 The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends in Molecular Medicine 14 109-119. (doi:10.1016/j.molmed.2007.12.007)
125. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG & El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERa expression in breast cancer cells. Molecular Endocrinology 15 1344-1359. (doi:10.1210/mend.15.8.0678)
126. Oida K, Matsuda A, Jung K, Xia Y, Jang H, Amagai Y, Ahn G, Nishikawa S, Ishizaka S, Jensen-Jarolim E et al. 2014 Nuclear factor-κB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Scientific Reports 4 4057. (doi:10.1038/srep04057)
127. Osborne CK & Schiff R 2011 Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine 62 233-247. (doi:10.1146/annurev-med-070909-182917)
128. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361. (doi:10.1093/jnci/95.5.353)
129. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C & Fridman WH 2010 Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29 1093-1102. (doi:10.1038/onc.2009.416)
130. Pan X, Zhou T, Tai YH, Wang C, Zhao J, Cao Y, Chen Y, Zhang PJ, Yu M, Zhen C et al. 2011 Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nature Medicine 17 708-714. (doi:10.1038/nm.2369)
131. Patani N & Martin LA 2014 Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Molecular and Cellular Endocrinology 382 683-694. (doi:10.1016/j.mce.2013.09.038)
132. Peddi PF, Ellis MJ & Ma C 2012 Molecular basis of triple negative breast cancer and implications for therapy. International Journal of Breast Cancer 2012 217185. (doi:10.1155/2012/217185)
133. Pradhan M, Bembinster LA, Baumgarten SC & Frasor J 2010 Proinflammatory cytokines enhance estrogen-dependent expression of the multi-drug transporter gene ABCG2 through estrogen receptor and NFκB cooperativity at adjacent response elements. Journal of Biological Chemistry 285 31100-31106. (doi:10.1074/jbc.M110.155309)
134. Pradhan M, Baumgarten SC, Bembinster LA & Frasor J 2012 CBP mediates NF-κB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter. Molecular and Cellular Biology 32 569-575. (doi:10.1128/MCB.05869-11)
135. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X & Perou CM 2010 Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research 12 R68. (doi:10.1186/bcr2635)
136. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR & Jorcyk CL 2005 Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Research 65 8896-8904. (doi:10.1158/0008-5472.CAN-05-1734)
137. Reiman JM, Kmieciak M, Manjili MH & Knutson KL 2007 Tumor immunoediting and immunosculpting pathways to cancer progression. Seminars in Cancer Biology 17 275-287. (doi:10.1016/j.semcancer.2007.06.009)
138. Reiman JM, Knutson KL & Radisky DC 2010 Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Research 70 3005-3008. (doi:10.1158/0008-5472.CAN-09-4041)
139. Richards CD 2013 The enigmatic cytokine oncostatin M and roles in disease. ISRN Inflammation 2013 512103. (doi:10.1155/2013/512103)
140. Riggins RB, Schrecengost RS, Guerrero MS & Bouton AH 2007 Pathways to tamoxifen resistance. Cancer Letters 256 1-24. (doi:10.1016/j.canlet.2007.03.016)
141. Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M et al. 2006 Interleukin-6, multidrug resistance protein-1 expression and response topaclitaxelinwomen with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Research and Treatment 100 301-308. (doi:10.1007/s10549-006-9251-7)
142. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG & Carroll JS 2011 Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal 30 3019-3027. (doi:10.1038/emboj.2011.216)
143. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R & de Miguel MP 2004 Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. Journal of Pathology 202 41-49. (doi:10.1002/path.1476)
144. Rubio MF, Werbajh S, Cafferata EG, Quaglino A, Colo GP, Nojek IM, Kordon EC, Nahmod VE & Costas MA 2006 TNF-α enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene 25 1367-1377. (doi:10.1038/sj.onc.1209176)
145. Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S & Brodie AM 2011 Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Research 71 1893-1903. (doi:10.1158/0008-5472.CAN-10-2458)
146. Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY & Van Laere SJ 2012 The interaction between ER and NFκB in resistance to endocrine therapy.Breast Cancer Research 14 212.(doi:10.1186/bcr3196)
147. Schiff R & Osborne CK 2005 Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Research 7 205-211. (doi:10.1186/bcr1287)
148. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK & Osborne CK 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research 10 331S-336S. (doi:10.1158/1078-0432.CCR-031212)
149. Schreiber RD, Old LJ & Smyth MJ 2011 Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 1565-1570. (doi:10.1126/science.1203486)
150. Schroder JM & Harder J 2006 Antimicrobials kinpeptides and proteins. Cellular and Molecular Life Sciences 63 469-486. (doi:10.1007/s00018-005-5364-0)
151. Scott DL 2012 Biologics-based therapy for the treatment of rheumatoid arthritis. Clinical Pharmacology and Therapeutics 91 30-43. (doi:10.1038/clpt.2011.278)
152. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H & Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 96 926-935. (doi:10.1093/jnci/djh166)
153. Simanski M, Rademacher F, Schroder L, Schumacher HM, Glaser R & Harder J 2013 IL-17A and IFN-γ synergistically induce RNase 7 expression via STAT3 in primary keratinocytes. PLoS ONE 8 e59531. (doi:10.1371/journal.pone.0059531)
154. Skliris GP, Leygue E, Curtis-Snell L, Watson PH & Murphy LC 2006 Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours. British Journal of Cancer 95 616-626. (doi:10.1038/sj.bjc.6603295)
155. Skliris GP, Lewis A, Emberley E, Peng B, Weebadda WK, Kemp A, Davie JR, Shiu RP, Watson PH & Murphy LC 2007 Estrogen receptor-β regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Research and Treatment 104 75-85. (doi:10.1007/s10549-006-9390-x)
156. Skliris GP, Leygue E, Watson PH & Murphy LC 2008 Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. Journal of Steroid Biochemistry and Molecular Biology 109 1-10. (doi:10.1016/j.jsbmb.2007.12.010)
157. Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH & Murphy LC 2010 A phosphorylation code for oestrogen receptor-α predicts clinical outcome to endocrine therapy in breast cancer. Endocrine-Related Cancer 17 589-597. (doi:10.1677/ERC-10-0030)
158. Speirs V, Kerin MJ, Walton DS, Newton CJ, Desai SB & Atkin SL 2000 Direct activation of oestrogen receptor-α by interleukin-6 in primary cultures of breast cancer epithelial cells. British Journal of Cancer 82 1312-1316. (doi:10.1054/bjoc.1999.1097)
159. Stearns V, Zhou Q & Davidson NE 2007 Epigenetic regulation as a new target for breast cancer therapy. Cancer Investigation 25 659-665. (doi:10.1080/07357900701719234)
160. Stossi F, Madak-Erdogan Z & Katzenellenbogen BS 2012a Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus. Oncogene 31 1825-1834. (doi:10.1038/onc.2011.370)
161. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM & Hall BM 2009 Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28 2940-2947. (doi:10.1038/onc.2009.180)
162. Taniguchi K & Karin M 2014 IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology 26 54-74. (doi:10.1016/j.smim.2014.01.001)
163. Teschendorff AE, Journee M, Absil PA, Sepulchre R & Caldas C 2007a Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Computational Biology 3 e161. (doi:10.1371/journal.pcbi.0030161)
164. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO & Caldas C 2007b An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biology 8 R157. (doi:10.1186/gb-2007-8-8-r157)
165. Tiffen PG, Omidvar N, Marquez-Almuina N, Croston D, Watson CJ & Clarkson RW 2008 A dual role for oncostatin M signaling in the differentiation and death of mammary epithelial cells in vivo. Molecular Endocrinology 22 2677-2688. (doi:10.1210/me.2008-0097)
166. Underhill-Day N & Heath JK 2006 Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor β-specific kernel. Cancer Research 66 10891-10901. (doi:10.1158/0008-5472.CAN-06-1766)
167. Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, Artemov D, Kowalski J, Carraway H, van Diest P et al. 2012 Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-a. Oncogene 31 3223-3234. (doi:10.1038/onc.2011.483)
168. Vlaicu P, Mertins P, Mayr T, Widschwendter P, Ataseven B, Hogel B, Eiermann W, Knyazev P & Ullrich A 2013 Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer 13 197. (doi:10.1186/1471-2407-13-197)
169. Vona-Davis L & Rose DP 2013 The obesity-inflammation-eicosanoid axis in breast cancer. Journal of Mammary Gland Biology and Neoplasia 18 291-307. (doi:10.1007/s10911-013-9299-z)
170. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D & Sonenshein GE 2007 Oestrogen signalling inhibits invasive pheno-type by repressing RelB and its target BCL2. Nature Cell Biology 9 470-478. (doi:10.1038/ncb1559)
171. Wang X, Belguise K, O'Neill CF, Sanchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V et al. 2009 RelB NF-κB represses estrogen receptor a expression via induction of the zinc finger protein Blimp1. Molecular and Cellular Biology 29 3832-3844. (doi:10.1128/MCB.00032-09)
172. Webb M, Emberley ED, Lizardo M, Alowami S, Qing G, Alfia'ar A, Snell-Curtis LJ, Niu Y, Civetta A, Myal Y et al. 2005 Expression analysis of the mouse S100A7/psoriasin gene in skin inflammation and mammary tumorigenesis. BMC Cancer 5 17. (doi:10.1186/1471-2407-5-17)
173. Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH & Murphy LC 2006 Assessment of multiple different estrogen receptor-β antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Research and Treatment 100 23-31. (doi:10.1007/s10549-006-9229-5)
174. West NR & Watson PH 2010 S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene 29 2083-2092. (doi:10.1038/onc.2009.488)
175. West NR, Milne K, Truong PT, Macpherson N, Nelson BH & Watson PH 2011 Tumor-infiltrating lymphocytes predict response to anthracy-cline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Research 13 R126. (doi:10.1186/bcr3072)
176. West NR, Murphy LC & Watson PH 2012 Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer. Endocrine-Related Cancer 19 181-195. (doi:10.1530/ERC-11-0326)
177. West NR, Murray JI & Watson PH 2014 Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 33 1485-1494. (doi:10.1038/onc.2013.105)
178. Wolf R, Howard OM, Dong HF, Voscopoulos C, Boeshans K, Winston J, Divi R, Gunsior M, Goldsmith P, Ahvazi B et al. 2008 Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. Journal of Immunology 181 1499-1506. (doi:10.4049/jimmunol.181.2.1499)
179. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K, Volk HD, Sterry W & Sabat R 2006 IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. European Journal of Immunology 36 1309-1323. (doi:10.1002/eji.200535503)
180. Yan Y, Li X, Blanchard A, Bramwell VH, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH et al. 2013 Expression of both estrogen receptor-beta1 (ER-b1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-a)-negative early breast cancer (EBC). Annals of Oncology 24 1986-1993. (doi:10.1093/annonc/mdt132)
181. Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Shetuni B & Barsky SH 2010 ERa signaling through slug regulates E-cadherin and EMT. Oncogene 29 1451-1462. (doi:10.1038/onc.2009.433)
182. Younes M & Honma N 2011 Estrogen receptor b. Archives of Pathology & Laboratory Medicine 135 63-66. (doi:10.1043/2010-0448-RAR.1)
183. Zeisberg M & Neilson EG 2009 Biomarkers for epithelial-mesenchymal transitions. Journal of Clinical Investigation 119 1429-1437. (doi:10.1172/JCI36183)
184. Zhang XH, Giuliano M, Trivedi MV, Schiff R & Osborne CK 2013 Metastasis dormancy in estrogen receptor-positive breast cancer. Clinical Cancer Research 19 6389-6397. (doi:10.1158/1078-0432.CCR-13-0838)
185. Zitvogel L, Galluzzi L, Smyth MJ & Kroemer G 2013 Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39 74-88. (doi:10.1016/j.immuni.2013.06.014)
186. Zwart W, Theodorou V & Carroll JS 2011 Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley Interdisciplinary Reviews. Systems Biology and Medicine 3 216-230. (doi:10.1002/wsbm.109)